Abstract

In the past year two studies have been completed. The first has examined prostate specific antigen as a marker of prostatic cancer. Longitudinal analyses demonstrated a significant age adjusted difference in rate of change in PSA between subjects with prostate cancer, BPH and controls. At a time when PSA did not differ between BPH and prostate cancer subjects (5 years before diagnosis), rate of change in PSA was significantly greater in subjects with prostate cancer. The findings suggest that of change in PSA may be a sensitive and specific early marker for the development of prostate cancer. The second study estimated the PSA growth curves of BLSA participants with no evidence of prostate disease, BPH cases, and prostate cancer cases. Control participants exhibited minimal change in PSA thus suggesting that BPH is not a natural outcome of normal prostate growth, but is a separate pathogenic process. BPH cases showed a gradual and continuing acceleration in PSA with increasing age. Cancer cases exhibited an early slow linear phase of PSA growth followed by a rapid exponential growth phase.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Intramural Research (Z01)
Project #
1Z01AG000633-03
Application #
3789865
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Loeb, Stacy; Kettermann, Anna; Ferrucci, Luigi et al. (2008) The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol 54:978-979
Carter, H Ballentine; Kettermann, Anna; Ferrucci, Luigi et al. (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685-90
Carter, H Ballentine; Kettermann, Anna; Warlick, Christopher et al. (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359-64;discussion 2364-5
Maggio, Marcello; Blackford, Amanda; Taub, Dennis et al. (2006) Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27:725-8
Carter, H Ballentine; Ferrucci, Luigi; Kettermann, Anna et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-7
Parsons, J Kellogg; Carter, H Ballentine; Partin, Alan W et al. (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562-8
Parsons, J Kellogg; Carter, H Ballentine; Platz, Elizabeth A et al. (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14:2257-60
Platz, Elizabeth A; Rohrmann, Sabine; Pearson, Jay D et al. (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14:390-6
Berndt, Sonja I; Carter, H Ballentine; Landis, Patricia K et al. (2005) Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 21:686-90
Carter, H Ballentine; Landis, Patricia; Wright, E James et al. (2005) Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 173:2040-3

Showing the most recent 10 out of 21 publications